Sitemap | Helsinn Corporate

New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology

Data presented at the International Society of Paediatric Oncology (SIOP) Congress show Palonosetron is a valuable option for treating pediatric patie

10 young students from the sopraceneri area receive Helsinn Advanced Synthesis SA 2013/2014 Educational Scholarships

Helsinn and Chugai Pharma Marketing enter into agreement for rights of Anamorelin, currently in development for treatment of anorexia-cachexia syndrom

Helsinn Birex Pharmaceuticals wins two prestigious awards for its outstanding health and safety performance

Helsinn Group's representative office in China: official inauguration

Helsinn Group and EISAI announce FDA acceptance of New Drug application for investigational compound netupitant 300 mg + palonestron 0.50 mg (NEPA)

Helsinn and Italfarmaco reinforce their alliance through the grant of rights to phase-III ghrelin receptor agoni st Anamorelin in Italy

Presentato il rapporto di sostenibilità 2012 di Helsinn Advanced Synthesis SA, presente a Biasca da 30 anni

Data presented at the International Society of Paediatric Oncology (SIOP) Congress show Palonosetron is a valuable option for treating pediatric patients receiving moderately to highly emetogenic chemotherapy

FDA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)

Helsinn’s showcase as part of "Piazza Ticino" at CPhI 2014, October 7-9, 2014, in Paris

Pivotal Phase III Trial Data for anamorelinin ROMANA 1 and 2 Studies in Non-Small Cell Lung Cancer Patients with Anorexia-Cachexia Shows Significant Increase in Lean Body Mass, Body Weight and Improved Symptoms

Helsinn to provide independent educational grant support for a satellite symposium on Delivering Chemotherapy with Confidence

Helsinn Group Receives Positive CHMP Opinion for Akynzeo® (netupitant/palonosetron) for the Prevention of Chemotherapy Induced Nausea and Vomiting

HELSINN GROUP GRANTS STENDHAL INTERNATIONAL EXCLUSIVE RIGHTS TO THE DISTRIBUTION AND MARKETING OF NETUPITANT-PALONOSETRON (NEPA) IN MULTIPLE COUNTRIES

Helsinn to present at the 33rd Annual J.P. Morgan Healthcare Conference (January 12-15, 2015)

30 candeline per la Helsinn Advanced Synthesis di Biasca, all'Insegna della Solidarietà - Helsinn Advanced Synthesis Celebrates 30 Year Anniversary and Supports the Social Activities of Volunteer Associations

Helsinn Awards Scholarships for Advanced Synthesis Education to 11 Students for the Academic Year 2014/2015 - Borse di Studio Helsinn Advanced Synthesis 2014/2015 per 11 Giovani Studenti del Canton Ticino per 55.000.- CHF

Helsinn Publishes Sustainability Report for its Drug Product Manufacturing and Supply Operation in Ireland

Helsinn Advanced Synthesis Wins 2015 CMO Leadership Award

HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH MUNDIPHARMA FOR DISTRIBUTION AND LICENCE OF ANAMORELIN IN CHINA, HONG KONG AND MACAO

EXCLUSIVE AGREEMENTS WITH MUNDIPHARMA FOR DISTRIBUTION AND LICENCE OF ANAMORELIN IN BRAZIL & ACROSS KEY MARKETS IN THE MIDDLE EAST & NORTH AFRICA

HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH MUNDIPHARMA FOR DISTRIBUTION AND LICENSING OF NETUPITANT/PALONOSETRON (NEPA) IN BRAZIL

Helsinn and Zealand announce the advance of elsiglutide into Phase IIB development for the prevention of chemotherapy-induced diarrhea

Helsinn Group and Eisai Inc. Announce Inclusion of AKYNZEO® (netupitant/palonosetron) in 2015 NCCN® Antiemesis Guidelines

TGA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)

Helsinn Group to present data at 2015 ASCO

The EU Commission approves ALOXI® (palonosetron HCl) Injection to prevent nausea and vomiting due to chemotherapy in children as young as one month

Helsinn introduces Helsinn Integrative Care at the American Society of Clinical Oncology Annual Meeting

The EU Commission Approves Helsinn’s Akynzeo®(netupitant/palonosetron) for Prevention of Chemotherapy-Induced Nausea and Vomiting in European Union

Helsinn Group hosts a Satellite Symposium on best practice in treating nausea in cancer patients, at MASCC

HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH MUNDIPHARMA FOR THE DISTRIBUTION AND LICENCE OF ANAMORELIN IN SWITZERLAND AND LIECHTENSTEIN

HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH BIAL FOR DISTRIBUTION AND LICENCE OF ANAMORELIN IN SPAIN, PORTUGAL, ANGOLA AND MOZAMBIQUE

Additional data for anamorelin in ROMANA 1 and ROMANA 2 studies

Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo®) in the UK by Chugai Pharma UK Ltd

HELSINN GROUP AWARDED GLOBAL CEO CANCER GOLD STANDARD ACCREDITATION

Helsinn Reaches Settlement Agreement Regarding Patent Dispute on ALOXI®

Helsinn’s AKYNZEO® (netupitant/palonosetron) nominated within the category “Best Pharmaceutical Agent of the Year” at The Galien Foundation Prix Award

Helsinn Group and Eisai Inc. Announce Inclusion of AKYNZEO® (netupitant/palonosetron) in American Society of Clinical Oncology (ASCO) Antiemetics Guid

SUCCESSFUL RULING IN PATENT INFRINGEMENT LITIGATION FOR ANTIEMETIC AGENT ALOXI® IN THE UNITED STATES

11 HELSINN ADVANCED SYNTHESIS 2014/2015 EDUCATIONAL SCHOLARSHIPS AWARDED TO YOUNG STUDENTS IN CANTON TICINO FOR 55.000 CHF

HELSINN ANNOUNCES EUROPEAN MEDICINES AGENCY ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION FOR ANAMORELIN HCL

Swissmedic approves Akynzeo® (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Switzerland

HELSINN CELEBRATES ITS 40th ANNIVERSARY - ~ 40 years helping patients achieve a better quality of life ~

HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH MUNDIPHARMA FOR THE DISTRIBUTION AND LICENCE OF ANAMORELIN IN NORTHERN EUROPE COUNTRIES

Helsinn and Eisai Announce Revised U.S. Collaboration for CINV Franchise

Helsinn announces publication of anamorelin ROMANA 1 and ROMANA 2 Phase III studies in The Lancet Oncology

Helsinn presents Quality of Life, its first group sustainability report

Helsinn Advanced Synthesis SA Wins 2016 CMO Leadership Awards

Helsinn Supports the Development of NCCN Guidelines For Patients® on Nausea and Vomiting, with a Sponsorship Grant

HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH PURDUE PHARMA CANADA FOR THE DISTRIBUTION AND LICENSING RIGHTS OF AKYNZEO® (NETUPITANT/PALONOSETRON combo

Helsinn Healthcare,The University of Texas MD Anderson Cancer Center enter strategic alliance to improve life of patients conducting clinical studies

Helsinn supports Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care with research funding support

Helsinn announces top-line results of Phase IIb trial with elsiglutide for prevention of chemotherapy-induced diarrhea in colorectal cancer patients

Helsinn to Present at UBS Healthcare Conference in New York

Helsinn to present at ASCO pooled follow up efficacy data analysis from two Phase III studies for anamorelin in cachectic patients with NSCLC

HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH GRÜNENTHAL GROUP FOR THE REGISTRATION, MARKETING, PROMOTION AND SALES OF AKYNZEO®

Helsinn Group hosts a Satellite Symposium on shared decision making in supportive care, at MASCC on June 24

Helsinn Group signs agreement with Vifor Pharma for the promotion and distribution of ALOXI®

Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development of Pracinostat for the Treatment Myeloid Leukemia and Other Diseases

Helsinn and PatientsLikeMe Announce Results of NSCLC Patient Survey on Weight Loss

HELSINN ATTENDANCE AT CPHI 2016

HELSINN GROUP INTRODUCES HELSINN INVESTMENT FUND

Swissmedic approves ALOXI® for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Children in Switzerland

Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting - Data to be present

HELSINN ADVANCED SYNTHESIS 2016/2017 EDUCATION SCHOLARSHIPS FOR 11 STUDENTS IN CANTON TICINO FOR A TOTAL OF 55.000.-

Helsinn Integrative Care Announces 510(K) FDA Clearance for Medical Device Xonrid® Gel

Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Helsinn Attendance at J.P. Morgan Annual Healthcare Conference

Helsinn will attend at ASCO 2017

ESMO 2017 in Madrid

Helsinn Group Launches “Helsinn Cares” Patient Support Services

Mundipharma and Helsinn Group Expand Exclusive Licensing and Distribution Agreements for Leading Anti-emetic Products in Middle East, Africa, Latin America and Indonesia

DCAT 2017 - New York City

CPhI Japan-2017

Helsinn Provides Grant for ESMO’s Preceptorship Course on Supportive and Palliative Care

HELSINN SUPPORTING FIRST ESMO PRECEPTORSHIP ON SUPPORTIVE AND PALLIATIVE CARE

Palliative and Supportive Care in Oncology Symposium

Helsinn Advanced Synthesis announces investment - Helsinn Advanced Synthesis annuncia investimenti

Helsinn Collaborates with Lyfebulb to Support Patient-Driven Innovations for People with Cancer

Helsinn Advanced Synthesis wins across all categories 2017 CMO Leadership Awards

Helsinn Healthcare vs. Teva Pharmaceuticals on Aloxi® patent for the US market

HELSINN INVESTMENT FUND INVESTS IN AADI BIOSCIENCE

Helsinn Investment Fund leads the financial round in GreenBone

Helsinn appoints Eric Cornut to Board of Directors

Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Helsinn to Present at UBS Global Healthcare Conference in New York

Helsinn Birex Pharmaceuticals wins National Workplace Wellbeing Day Award

Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome

Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Sarah A. Buckley, MD, University of Washington

Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi® (palonosetron hydrochloride) in Canada

Zealand to regain control of elsiglutide

Helsinn Group Announces Upcoming Presentation of Phase III data in NEPA (netupitant/palonestron) at MASCC/ISOO Congress in Washington DC

APSHO

Chemotherapy Foundation Symposium - 2017

Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

CPhI Worldwide 2017

AMAL Therapeutics raises €8 million (CHF 8.8 million) in first closing of Series B financing round

Helsinn Therapeutics (U.S.) Inc., Signs Co-Promotion Agreement for Cancer Therapeutic Zykadia® in the US

Helsinn Group Announces Upcoming Presentation of Phase III data of NEPA (fosnetupitant/ palonosetron) IV at ESMO 2017

Helsinn Group supports prIME’s Satellite Symposium at ESMO 2017

Helsinn Advanced Synthesis 2017/2018 education scholarships for 10 students in canton Ticino for a total of 50.000.- CHF

Helsinn announces its support for the International Fellowship Program (IFP), a joint project founded by the Society for Translational Oncology (STO) and Chinese Society of Clinical Oncology (CSCO)

Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China

Helsinn Announces Attendance at the CPhI 2017 Conference in Frankfurt

A call for action to patient entrepreneurs in the area of cancer to compete at the Lyfebulb-Helsinn Summit for the first ever Lyfebulb- Helsinn Innovation Award

40th SAN ANTONIO BREAST CANCER SYMPOSIUM

59th ASH ANNUAL MEETING AND EXPOSITION

Helsinn Group supports Satellite Symposium at 10th International Conference on Cachexia, Sarcopenia and Muscle Wasting

Helsinn to honor Anna Braglia Endowed Young Investigator Award recipient at Helsinn reception during JP Morgan Healthcare Conference 2018

A call for action to patient entrepreneurs in the area of cancer to compete at the Lyfebulb-Helsinn Summit for the first ever Lyfebulb - Helsinn Innovation Award

Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)

US Court of Appeals for Federal Circuit Rejects Petition by Helsinn for Rehearing En Banc of Federal Circuit Panel Ruling That Certain Patents Covering Aloxi® in the US Market Are Invalid

Borse di studio Helsinn Advanced Synthesis 2017/2018 per 10 studenti del canton Ticino per un valore complessivo di 50'000.- CHF

Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement

Helsinn Group announces the appointment of Paul Rittman as Chief Executive Officer, Helsinn Therapeutics (HTU)

Helsinn Files Petition for Writ of Certiorari for Supreme Court Review Regarding Patent Covering Aloxi® in the US Market

Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology

On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn

Helsinn Group Announces First Patient Enrolled in Phase 3b Study of NEPA IV vs NEPA Oral for the prevention of chemotherapy induced nausea and vomiting (CINV) in Women with Breast Cancer

Helsinn Group announces agreement to acquire worldwide rights to Valchlor®/Ledaga® - an approved and marketed alkylating agent for the topical treatment of mycosis fungoides‐type cutaneous T‐cell lymphoma, a rare type of skin cancer

Helsinn Advanced Synthesis wins across all categories at the 2018 CMO Leadership Awards

Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced

Helsinn Group and Glenmark Pharmaceuticals enter into an exclusive licensing agreement for launch of AKYNZEO® in India and Nepal

Helsinn Provides Grant for ESMO’s Preceptorship Programme for Supportive and Palliative Care

Transforming Breast Cancer Together: A Call for Change

VITAFOOD Europe 2018

ESTRO

Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy

Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/palonosetron) in the United States

Helsinn Group to Present a Poster at Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018

NovellusDx announces it has completed an equity financing of $6 million

Helsinn Group announces the launch of the IV formulation of AKYNZEO® (fosnetupitant/palonosetron) in the United States

Helsinn Group and Mundipharma announce the launch of AKYNZEO® hard capsule for oral use in Brazil

Helsinn announces EUR6 million investment in Helsinn Birex Pharmaceuticals to safeguard the quality and authenticity of its products

ASCO

MASCC

Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for standard ind

MEI Pharma and Helsinn Group Announce Successful Interim Analysis of Pracinostat/Azacitidine Phase 2 Combination Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients

Second Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Rajiv Agarwal, MD, Memorial Sloan Kettering Cancer Center

Helsinn Group and Angelini support Satellite Symposium at MASCC/ISOO 2018 Annual Meeting

The US Supreme Court Grants Review for Certiorari of a Federal Circuit Panel Ruling that US Patent Protection for Aloxi® in the US Market was Invalid

Helsinn Therapeutics (U.S.) Inc. becomes the exclusive distributor of ALOXI® (palonosetron HCI) in the U.S.

Glenmark Pharmaceuticals expands its oncology franchise in India with the launch of Helsinn’s AKYNZEO®, a combination drug for the prevention of chemotherapy-induced nausea and vomiting (CINV)

Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea

Mundipharma brings its cancer supportive care expertise to Vietnam after signing agreement with Helsinn Group for ALOXI® (palonosetron HCl)

Helsinn Group supports Satellite Symposium at EORTC CLTF 2018 Annual Meeting

ONO Submits an Application for Manufacturing and Marketing Approval of Anamorelin (ONO-7643), a ghrelin receptor antagonist, for the treatment of cancer cachexia in Japan

Helsinn Group strengthens the Board with the appointment of Francesco Granata - Il Gruppo Helsinn rafforza il Consiglio di Amministrazione con la nomina di Francesco Granata

EORTC

ESMO

EADO

Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018

Helsinn and Lyfebulb Announce Partnership for Second Annual Patient-Driven Innovation Summit in Cancer

Helsinn and Mundipharma China Pharmaceutical announce tha approval of ALOXI®IV by the National Medical Products Administration in China

Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting

Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US

Recordati and Helsinn Sign an Agreement for the Exclusive Commercialization Rights to Ledaga®

Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat

JP Morgan

CPhI Japan

DCAT

Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care

Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in the Frontline Treatment of Older AML Patients Unfit for Intensive Chemotherapy, in Blood Advance

Helsinn Investment Fund Invests €1 Million in Gain Therapeutics

Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology

Helsinn initiates two new global Phase III studies with anamorelin

Vitafoods Europe